Drug Makers Stocks under Review -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline

Aug 25, 2016, 07:30 ET from Chelmsford Park SA

NEW YORK, August 25, 2016 /PRNewswire/ --

Stock-Callers.com has initiated research reports on the following Major Drug Manufacturers in the Healthcare sector: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). On Wednesday, August 17, 2016, Brean Capital downgraded the sector to "Underweight" on technical indicators such as deteriorating relative strength, price momentum, and momentum of breadth. Learn more about these stocks by downloading their free research reports in PDF format at: http://stock-callers.com/registration

Bristol-Myers Squibb  

At the close on Wednesday, shares in New York headquartered Bristol-Myers Squibb Co. saw a decline of 2.12%, ending the day at $58.59. The stock recorded a trading volume of 13.19 million shares, which was above its three months average volume of 9.19 million shares. The Company's shares are trading below their 200-day moving average by 12.71%. Moreover, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide, have a Relative Strength Index (RSI) of 27.71.

On August 11th, 2016, research firm Berenberg downgraded the Company's stock rating from 'Buy' to 'Hold'.

On August 05th, 2016, Bristol-Myers Squibb announced that CheckMate-026, a trial investigating the use of Opdivo (nivolumab) as monotherapy, did not meet its primary endpoint of progression-free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 at = 5%. Sign up and read the free research report on BMY at: http://stock-callers.com/registration/?symbol=BMY


Shares in London, the UK headquartered AstraZeneca PLC ended the day 0.98% lower at $33.50 and with a total volume of 5.42 million shares traded. The stock has gained 9.83% in the last month, 13.23% in the previous three months, and 3.23% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 8.33% and 11.51%, respectively. Furthermore, shares of AstraZeneca, which engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide, have an RSI of 64.90.

On August 24th, 2016, Reuters reported that AstraZeneca had agreed to sell its small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5 billion. The portfolio includes approved antibiotics Merrem, Zinforo, and Zavicefta, and ATM-AVI and CXL, which are in clinical development. Pfizer will pay $550 million upon completion and a further unconditional $175 million in January 2019, plus up to $250 million in milestones, up to $600 million in sales-related payments and recurring, double-digit royalties on future sales of Zavicefta and ATM-AVI in certain markets. The complimentary research report on AZN can be downloaded at: http://stock-callers.com/registration/?symbol=AZN

Eli Lilly  

On Wednesday, shares in Indianapolis, Indiana headquartered Eli Lilly and Co. finished 1.42% lower at $78.44 with a total volume of 2.80 million shares traded. The stock has advanced 5.90% over the previous three months. The Company's shares are trading above their 200-day moving average by 1.76%. Additionally, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 40.87.

On August 10th, 2016, Eli Lilly announced that following a pre-planned interim analysis for MONARCH 2, an independent Data Monitoring Committee provided the recommendation to continue the study without modification as the interim efficacy criteria were not met. The trial will continue into the first half of 2017 and will include a final analysis of PFS, overall survival and safety data. Lilly will await further data and continue to work with the FDA to inform its submission plan for single-agent abemaciclib, based on the MONARCH 1 study.  Register for free on Stock-Callers.com and access the latest report on LLY at: http://stock-callers.com/registration/?symbol=LLY


Brentford, the UK headquartered GlaxoSmithKline PLC's stock recorded a trading volume of 2.60 million shares at the end of yesterday's session and closed the day at $43.90, declining 1.15%. The stock has advanced 0.54% in the last one month, 2.97% in the previous three months, and 15.03% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 1.93% and 8.90%, respectively. Additionally, shares of GlaxoSmithKline, which creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide, have an RSI at 53.73.

On August 1st, 2016, Bloomberg reported that GlaxoSmithKline is forming a joint venture with Google parent Alphabet Inc.'s life-sciences business to explore using electrical signals to treat diseases. GlaxoSmithKline will hold a 55% stake in the venture, called Galvani Bioelectronics, and Alphabet's Verily Life Sciences LLC will hold 45%. The companies will invest up to 540 million pounds ($715 million) over seven years if the research and development efforts meet certain goals. Get free access to your research report on GSK at: http://stock-callers.com/registration/?symbol=GSK


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA